European Pharmacopoeia Ph Eur Monograph Tablets 0478 Better [portable] Jun 2026

Your (e.g., direct compression, wet granulation, dry granulation)

The Ph. Eur. Monograph 0478 structures tablet criteria into distinct pillars: . These guidelines guarantee that oral dosage forms behave predictably throughout their shelf life.

: Formulated to alter the rate, place, or time of drug release (sustained or delayed).

The European Directorate for the Quality of Medicines & HealthCare (EDQM) frequently updates this monograph to reflect advancing manufacturing technologies. european pharmacopoeia ph eur monograph tablets 0478 better

Tablets must be physically robust enough to withstand mechanical stress during film coating, packaging, shipping, and handling by the consumer.

Simple matrices that release active substances without delayed barrier coatings.

defines tablets as "solid preparations each containing a single dose of one or more active substances." They are obtained by compressing uniform volumes of particles or by other methods of manufacture (e.g., moulding). Your (e

aim to further align disintegration and dissolution tests across the Ph. Eur., USP, and JP. Policy Shift (2020)

Monograph 0478 dictates the core baseline properties that every tablet must possess before it can be legally marketed in the European Directorate for the Quality of Medicines & HealthCare (EDQM) member states. It outlines specific definitions, production requirements, and critical end-product testing procedures. Scope and Classifications

By designing testing protocols that meet the stringent demands of Ph. Eur. Monograph 0478, manufacturers often inherently satisfy global regulatory expectations, facilitating smoother multi-market registrations and broader market access. These guidelines guarantee that oral dosage forms behave

While other pharmacopoeias (USP, BP) have similar standards, adherence to the European Pharmacopoeia is generally considered a higher bar for quality, particularly regarding the rigor of subdivision testing and strict uniformity requirements for low-dose APIs (Active Pharmaceutical Ingredients). Conclusion

The breakdown speed of the tablet matrix is tightly regulated.

For compliance and quality assurance teams, adopting these revised standards is not just a regulatory necessity—it is an investment in product excellence.

If a tablet is intended to be divided, the divided parts must meet strict uniformity of mass requirements , ensuring that the patient receives the correct dosage.